Approved influenza vaccine uses microinjection delivery system

Share this content:
Approved influenza vaccine uses microinjection delivery system
Approved influenza vaccine uses microinjection delivery system
The Food and Drug Administration has approved Sanofi Pasteur's licensure application for Fluzone Intradermal. This vaccine is indicated for active immunization of adults against influenza disease caused by influenza virus subtypes A and B. "The microinjection delivery system utilized in Fluzone Intradermal vaccine provides reliable and easy delivery of the vaccine into the dermal layer of the skin, an attractive site for immunization," said Olivier Charmeil, the firm's chief executive.